Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Enliven Therapeutics Inc., 3 years.
Enliven Therapeutics Inc.
Director
PMV Pharmaceuticals Inc.
Director
Oric Pharmaceuticals Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Oric Pharmaceuticals Inc. June 12, 202475.4%
-
Enliven Therapeutics Inc. June 23, 202398.8%
-
PMV Pharmaceuticals Inc. June 8, 202381.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 24, 2026 | Oric Pharmaceuticals Inc. | Option exercise | +3,500 | $1.60 | $5,600 |
| Jul 24, 2026 | Oric Pharmaceuticals Inc. | Open-market sale | −7,000 | $12.02 | $84,140 |
| Jul 24, 2026 | Oric Pharmaceuticals Inc. | Open-market sale | −6,100 | $12.02 | $73,322 |
| Jul 6, 2026 | Oric Pharmaceuticals Inc. | Open-market sale | −300 | $12.00 | $3,600 |
| Feb 17, 2026 | Enliven Therapeutics Inc. | Open-market sale | −1,230 | $26.18 | $32,201 |
| Jan 20, 2026 | Enliven Therapeutics Inc. | Open-market sale | −512 | $26.46 | $13,548 |
| Jan 20, 2026 | Enliven Therapeutics Inc. | Open-market sale | −718 | $26.96 | $19,357 |
| Jan 16, 2026 | Oric Pharmaceuticals Inc. | Open-market sale | −3,500 | $12.00 | $42,000 |
| Jan 16, 2026 | Oric Pharmaceuticals Inc. | Open-market sale | −3,200 | $12.00 | $38,400 |
| Jan 9, 2026 | Enliven Therapeutics Inc. | Open-market sale | −4,285 | $25.00 | $107,125 |
| Jan 8, 2026 | Enliven Therapeutics Inc. | Open-market sale | −1,620 | $25.00 | $40,500 |
| Jan 8, 2026 | Enliven Therapeutics Inc. | Open-market sale | −8,015 | $25.04 | $200,696 |
| Oct 3, 2025 | Oric Pharmaceuticals Inc. | Option exercise | +31,353 | $1.60 | $50,165 |
| Oct 3, 2025 | Oric Pharmaceuticals Inc. | Option exercise | +1,447 | $3.75 | $5,426 |
| Oct 18, 2024 | Enliven Therapeutics Inc. | Open-market sale | −817 | $30.00 | $24,510 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.